PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Travel distance and stereotactic body radiotherapy for localized prostate cancer.

Abstract Definitive stereotactic body radiotherapy (SBRT) represents an emerging and debated treatment option for patients with prostate cancer, with potential economic savings and reports of short-term efficacy since 2006. The current study sought to define national trends in definitive prostate SBRT use and determine whether patterns vary by travel distance for treatment.
PMID
Related Publications

Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.

The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.

Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.

Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.

Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.

Authors

Mayor MeshTerms
Keywords

financial toxicity

prostate cancer

radiation

stereotactic body radiotherapy (SBRT)

travel distance

Journal Title cancer
Publication Year Start




PMID- 29231964
OWN - NLM
STAT- Publisher
LR  - 20171212
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
DP  - 2017 Dec 12
TI  - Travel distance and stereotactic body radiotherapy for localized prostate cancer.
LID - 10.1002/cncr.31190 [doi]
AB  - BACKGROUND: Definitive stereotactic body radiotherapy (SBRT) represents an
      emerging and debated treatment option for patients with prostate cancer, with
      potential economic savings and reports of short-term efficacy since 2006. The
      current study sought to define national trends in definitive prostate SBRT use
      and determine whether patterns vary by travel distance for treatment. METHODS:
      The National Cancer Data Base identified 181,544 men with localized prostate
      cancer who were treated with definitive external beam radiotherapy from 2004
      through 2012. Joinpoint regression analyzed definitive prostate SBRT trends over 
      time, whereas multivariable logistic regression defined the odds for its receipt 
      by travel distance for treatment. RESULTS: Definitive prostate SBRT use increased
      from 1.8% in 2004 to 5.9% in 2012 (P for trend <.0001), with a joinpoint for
      increased use noted in 2006 (P<.0001). Higher SBRT use was found to be associated
      with longer travel distance for treatment, younger age, white race, more affluent
      zip code of residence, academic treatment center, favorable disease
      characteristics, and fewer comorbidities (all P<.0001). Compared with travel
      distances <25 miles for treatment, travel distances of 25 to 50 miles and >50
      miles were associated with increasing adjusted odds of receipt of definitive
      prostate SBRT (1.63 [95% confidence interval, 1.51-1.76] and 2.35 [95% confidence
      interval, 2.14-2.57], respectively; both P < .0001). CONCLUSIONS: Definitive
      prostate SBRT use increased more than 3-fold since 2004, with a significant
      increase in use coinciding with early reports of short-term efficacy.
      Long-distance travel for treatment was associated with greater than twice the
      odds of receipt of definitive prostate SBRT compared with short-distance travel, 
      suggesting that treatment decisions with unknown long-term clinical implications 
      may be strongly driven by sociodemographic factors. Cancer 2017. (c) 2017
      American Cancer Society.
CI  - (c) 2017 American Cancer Society.
FAU - Mahal, Brandon A
AU  - Mahal BA
AUID- ORCID: http://orcid.org/0000-0003-3036-334X
AD  - Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts.
FAU - Chen, Yu-Wei
AU  - Chen YW
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.
FAU - Sethi, Roshan V
AU  - Sethi RV
AD  - Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts.
FAU - Padilla, Oscar A
AU  - Padilla OA
AD  - Tufts University School of Medicine, Boston, Massachusetts.
FAU - Yang, David D
AU  - Yang DD
AD  - Harvard Medical School, Boston, Massachusetts.
FAU - Chavez, Janice
AU  - Chavez J
AD  - Department of Social Work, Brigham and Women's Hospital, Boston, Massachusetts.
FAU - Muralidhar, Vinayak
AU  - Muralidhar V
AD  - Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts.
FAU - Hu, Jim C
AU  - Hu JC
AD  - Department of Urology, Weill Cornell Medicine, New York, New York.
FAU - Feng, Felix Y
AU  - Feng FY
AD  - Department of Radiation Oncology, University of California at San Francisco, San 
      Francisco, California.
FAU - Hoffman, Karen E
AU  - Hoffman KE
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, Texas.
FAU - Martin, Neil E
AU  - Martin NE
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and
      Women's Hospital, Boston, Massachusetts.
FAU - Spratt, Daniel E
AU  - Spratt DE
AUID- ORCID: http://orcid.org/0000-0002-5973-4741
AD  - Department of Radiation Oncology, University of Michigan Health System, Ann
      Arbor, Michigan.
FAU - Yu, James B
AU  - Yu JB
AD  - Department of Therapeutic Radiology/Radiation Oncology, Yale University, New
      Haven, Connecticut.
FAU - Orio, Peter F 3rd
AU  - Orio PF 3rd
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and
      Women's Hospital, Boston, Massachusetts.
FAU - Nguyen, Paul L
AU  - Nguyen PL
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and
      Women's Hospital, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
DEP - 20171212
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
OTO - NOTNLM
OT  - financial toxicity
OT  - prostate cancer
OT  - radiation
OT  - stereotactic body radiotherapy (SBRT)
OT  - travel distance
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/10/06 00:00 [received]
PHST- 2017/10/29 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - 10.1002/cncr.31190 [doi]
PST - aheadofprint
SO  - Cancer. 2017 Dec 12. doi: 10.1002/cncr.31190.